Avid Bioservices Inc (CDMO)

[pphmtoolong]

As usual the focus here seems to be on everything except the FDA approval and the commercialization potential of Bavituximab vs the cost of development.

Talking about the development cost alone, i.e.dilution, is pointless unless it is in the context of the commercial potential of Bavi. If Peregrine has 400 million shares, but grosses $3 billion a year I think shareholders will be just fine. If it only grosses $1 billion a year, I'm not sure shareholders will be happy. See my point?

I want to know how soon Bavi can be approved. I want to know how many indications will be commercially significant for Bavi. Is it lung, breast and skin cancers? More? Less? How much market share might Bavi expect? How much would that gross for Peregrine?

How much might it cost Peregrine to go it alone? What does 'go it alone' mean? Are there distribution companies that would handle the entire process? What does advertising cost for a new cancer fighting drug? Is it targeted to physicians? Patients? Medicare? Insurance companies?

There are many real questions effecting the success or failure of Peregrine. Too bad we focus so much time on side issues. We all know what they are.

GLTA, Especially Bavi-arm Sunrise Patients,

Paul